A proposed 12-year protection for biotech drugs from generic competition would have huge implications for taxpayers and businesses, particularly in California. A large portion of the budget for research in the industry comes from the NIH, and Medicare and Medicaid cover a significant portion of the cost of biotech treatments. Biotechnology and venture capital firms, many of which reside in California, want the exclusivity so they can protect their multimillion-dollar investments in developing biologics.

Related Summaries